Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE-45 study of ENTR-601-45 in Duchenne muscular dystrophy amenable to exon 45 skipping
2024-517499-39-00Phase 2Authorised
- Sponsor
- Entrada Therapeutics
- Start
- Jul 2025
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of ENTR-601-45 in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Entrada Therapeutics. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Change in vital signs and 3 more. Planned start Jul 2025; status: authorised.
02
Drugs
ENTR-601-45
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2024-517499-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517499-39-00.